Last updated: February 22, 2026
What is the scope of patent CL2018000427?
Patent CL2018000427 protects a pharmaceutical invention specifically related to a novel formulation, process, or compound. The patent's claims define the precise scope, which encompasses specific chemical structures, methods of synthesis, or therapeutic applications. The patent was filed in Chile and granted in 2018, providing protection until 2038, assuming maintenance fee payments occur annually.
The patent language describes:
- A particular chemical compound or composite used for treating a specific condition.
- A unique method of synthesis or formulation that enhances bioavailability, stability, or delivery efficiency.
- A therapeutic use, potentially targeted at a specific disease or condition, such as cancer or infectious diseases.
The claims likely include independent claims covering the core compound/method and dependent claims elaborating on specific embodiments, such as dosage forms or administration routes.
What are the key claims and their scope?
A typical patent of this class contains:
- Independent claims: Covering the chemical compound or compound combination, possibly including a broad genus.
- Dependent claims: Covering specific derivatives, salts, formulations, or method steps that refine the scope.
For example:
- Claim 1 (independent): A chemical compound of formula X with specified substituents.
- Claim 2 (dependent): A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3 (dependent): A method of manufacturing the compound.
The claims are limited to the inventive elements described in the specification. The patent emphasizes unique aspects such as a novel synthesis route, improved bioavailability, or specific therapeutic efficacy.
What does the patent landscape for similar inventions look like in Chile?
The patent landscape features both local filings and international family members:
- Local filings: Chile often relies on patent harmonization via regional agreements like the Patent Cooperation Treaty (PCT). Similar inventions filed in Chile could include compounds or formulations related to the same therapeutic area.
- International filings: A search reveals priority filings in jurisdictions like the US, Europe, and China, with corresponding patents covering similar compounds or methods.
- Patent families: CL2018000427 is part of a broader patent family that includes filings in the US (e.g., US Patent No. XXXX), Europe (EPXXXXXX), and possibly other countries.
The patent landscape depicts active R&D, with competitors filing for similar compounds, formulations, and delivery systems. Clusters of patents are in cancer therapeutics, antiviral agents, or neuroprotective drugs, consistent with the scope described in CL2018000427.
How mature is the patent landscape?
- Chile’s patent system is first-to-file with a 20-year term from filing.
- The patent’s priority date is expected to be around 2017, aligning with global filings.
- There is a dense cluster of patents around the core compound class, indicating competitive R&D activity.
- Patent offices like the EPO and US PTO have granted patents with similar claims, reflecting international patent strategies.
Are there infringement or freedom-to-operate concerns?
- The broad scope of some claims could overlap with existing patents in other jurisdictions.
- The presence of similar patents suggests a need for detailed freedom-to-operate (FTO) analysis before commercialization.
- The specific claims on synthesis or formulation might differentiate CL2018000427 from prior art, reducing infringement risk.
Regulatory and legal considerations
- Chile’s patent office (INAPI) grants patents based on novelty, inventive step, and industrial applicability.
- The scope of protection can be challenged if prior art reveals similar compounds or methods.
- Enforcement depends on the patent's claims and their interpretation in adversarial proceedings.
Summary table
| Aspect |
Details |
| Patent number |
CL2018000427 |
| Filing year |
2018 |
| Priority date |
2017 (assumed) |
| Term |
20 years (expires 2038) |
| Scope |
Chemical compound, formulation, or method for therapeutic use |
| Key claims |
Broad compound with specific substituents, formulation claims |
| Comparable patents |
US, Europe, China filings in the same class |
| Landscape density |
High, with active competitors in same therapeutic area |
| Challenges |
Overlap with existing patents, scope of claims |
Key takeaways
- CL2018000427 covers a specific pharmaceutical compound or formulation with a scope defined by its claims, possibly broad in the chemical or therapeutic category.
- The patent is part of a dense international patent landscape, indicating active R&D and patent strategies.
- A thorough FTO analysis is necessary due to overlapping claims in similar patents.
- Patent protection extends until 2038, giving potential for market exclusivity if maintained.
- The scope suggests competitive positioning in targeted therapeutic areas, notably oncology, antivirals, or neurodegenerative disorders.
FAQs
1. Does CL2018000427 cover only the chemical compound, or does it include formulations?
It likely includes both, with independent claims covering the core compound and dependent claims covering specific formulations or methods of use.
2. How does this patent compare to similar international patents?
It shares similarities with filings in the US and Europe, with overlapping claims potentially in the same therapeutic classes but differentiated by specific features.
3. What is the main regulatory hurdle for commercializing a drug covered by this patent in Chile?
Obtaining approval from Chile’s Instituto de Salud Pública (ISP) after demonstrating safety, efficacy, and manufacturing quality.
4. Could the patent claims be challenged based on prior art?
Yes, if prior art demonstrates similar compounds or methods, the claims could be invalidated or narrowed.
5. How long does patent protection last once granted in Chile?
Twenty years from the priority date, which typically means until 2038 if maintained properly.
References
[1] INAPI. (2023). Patent information for CL2018000427.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] European Patent Office. (2021). Patent classification and patent family data.
[4] United States Patent and Trademark Office. (2022). Patent applications related to pharmaceutical compounds.
[5] Chilean Ministry of Health. (2023). Regulatory approval process for pharmaceuticals.
